Robert L Coffman, PhD
Affiliations: | Dynavax Technologies |
Area:
ImmunologyWebsite:
https://www.soe.ucsc.edu/people/rcoffmanGoogle:
"Robert Lee Coffman" OR "Robert L Coffman"Bio:
http://www.nasonline.org/member-directory/members/9160.html
http://investors.dynavax.com/news-releases/news-release-details/dynavax-chief-scientific-officer-robert-l-coffman-phd-elected
https://books.google.com/books?id=lHwCT44FnEIC
Parents
Sign in to add mentor| Melvin Cohn | grad student | 1976 | UCSD (Chemistry Tree) | |
| (The Class of Surface Immunoglobulin on Virgin and Memory B Lymphocytes) | ||||
| Irving L. Weissman | post-doc | 1977-1981 | Stanford | |
Children
Sign in to add trainee| Walderez Dutra | grad student | Federal University of Minas Gerais, Brasil | |
| Kenneth Gollob | grad student | AC Camargo Cancer Center | |
| Amy Beebe | post-doc | Merck & Co. | |
| Rodrigo Correa-Oliveira | post-doc | FIOCRUZ, Belo Horizonte | |
| Daniel Cua | post-doc | Johnson & Johnson Pharmaceutical Research and Development, Spring House, Pennsylvania | |
| T. Mark Doherty | post-doc | State Serum Institute, Denmark | |
| Edith Hessel | post-doc | Glaxo Smith Kline | |
| Stephen Hurst | post-doc | Genentech, Inc. | |
| Valerie Julia | post-doc | Université de Nice, France | |
| Fiona M Powrie | post-doc | Kennedy institute of Rheumatology | |
| Huub Savelkoul | post-doc | Wageningen University |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Leong WI, Ames RY, Haverkamp JM, et al. (2019) Low-dose metronomic cyclophosphamide complements the actions of an intratumoral C-class CpG TLR9 agonist to potentiate innate immunity and drive potent T cell-mediated anti-tumor responses. Oncotarget. 10: 7220-7237 |
| Kell SA, Kachura MA, Renn A, et al. (2019) Preclinical development of the TLR9 agonist DV281 as an inhaled aerosolized immunotherapeutic for lung cancer: Pharmacological profile in mice, non-human primates, and human primary cells. International Immunopharmacology. 66: 296-308 |
| Degagné É, Romo J, Gallotta M, et al. (2019) Abstract 2259: Tumor abscopal responses induced by the TLR9 agonist, SD-101, are strongly potentiated by a HDAC class I inhibitor, domatinostat Cancer Research. 79: 2259-2259 |
| Ribas A, Medina T, Kummar S, et al. (2018) SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase 1b, Multicenter Study. Cancer Discovery |
| Frank MJ, Reagan PM, Bartlett NL, et al. (2018) In Situ Vaccination with a TLR 9 Agonist and Local Low Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma. Cancer Discovery |
| Gallotta M, Assi H, Degagné É, et al. (2018) Inhaled TLR9 Agonist Renders Lung Tumors Permissive to PD-1 Blockade by Promoting Optimal CD4+ and CD8+ T cell Interplay. Cancer Research |
| Jackson S, Candia AF, Delaney S, et al. (2017) First-in-human study with the inhaled TLR9 oligonucleotide agonist AZD1419 results in interferon responses in the lung, and is safe and well-tolerated. Clinical Pharmacology and Therapeutics |
| Sato-Kaneko F, Yao S, Ahmadi A, et al. (2017) Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. Jci Insight. 2 |
| Candia A, Guiducci C, Coffman RL, et al. (2017) Abstract LB-239: Pharmacodynamic changes confirm the mechanism of action mediating SD-101 efficacy, in combination with pembrolizumab, in a phase 1b/2 study in metastatic melanoma (MEL-01) Cancer Research. 77 |
| Naik E, Ying C, Milley R, et al. (2017) Abstract 5596: Intratumoral administration of a TLR9-adjuvanted nanoparticle cancer vaccine stimulates more effective immunity in both injected and un-injected tumor sites compared to subcutaneous administration Cancer Research. 77: 5596-5596 |